Literature DB >> 3548618

Alfred Blalock and thymectomy for myasthenia gravis.

P A Kirschner.   

Abstract

In 1936, Alfred Blalock performed the successful removal of a thymic tumor in a patient with myasthenia gravis. The patient experienced marked and sustained improvement for several years. Blalock prophesized then that exploration of the thymic region would be indicated in all patients with severe myasthenia gravis. A few years later, in 1941, he applied this theory by introducing thymectomy for nonthymomatous myasthenia and achieved similar improvement. Despite modern sophisticated knowledge about the disease and advances in thoracic surgical techniques, Blalock's original observations remain valid, and thymectomy has become a standard treatment for myasthenia gravis the world over.

Entities:  

Mesh:

Year:  1987        PMID: 3548618     DOI: 10.1016/s0003-4975(10)60635-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis.

Authors:  G B Bulkley; K N Bass; G R Stephenson; M Diener-West; S George; P A Reilly; R R Baker; D B Drachman
Journal:  Ann Surg       Date:  1997-09       Impact factor: 12.969

Review 2.  Long-term outcome and quality of life after thymectomy for myasthenia gravis.

Authors:  C Busch; A Machens; U Pichlmeier; T Emskötter; J R Izbicki
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

3.  Long-term outcome and quality of life after open and thoracoscopic thymectomy for myasthenia gravis: analysis of 131 patients.

Authors:  Kai Bachmann; Doreen Burkhardt; Inken Schreiter; Jussuf Kaifi; Christoph Busch; Gunther Thayssen; Jakob R Izbicki; Tim Strate
Journal:  Surg Endosc       Date:  2008-02-23       Impact factor: 4.584

Review 4.  Myasthenia gravis and the thymus gland. A historical review.

Authors:  Marius Raica; Anca Maria Cimpean; Domenico Ribatti
Journal:  Clin Exp Med       Date:  2008-07-11       Impact factor: 3.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.